Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Paul Ridker (1) , James Revkin , Pierre Amarenco (2, 3) , Robert Brunell , Madelyn Curto , Fernando Civeira , Marcus Flather , Robert Glynn , Jean Gregoire , J. Wouter Jukema , Yuri Karpov , John J.P. Kastelein , Wolfgang Koenig , Alberto Lorenzatti , Pravin Manga , Urszula Masiukiewicz , Michael Miller , Arend Mosterd , Jan Murin , Jose Nicolau , Steven Nissen , Piotr Ponikowski , Raul Santos , Pamela Schwartz , Handrean Soran , Harvey White , R. Scott Wright , Michal Vrablik , Carla Yunis , Charles Shear , Jean-Claude Tardif , Spire Cardiovascular Outcome Investigators

1 Brigham and Women's Hospital [Boston]
2 UPD7 - Université Paris Diderot - Paris 7
3 USPC - Université Sorbonne Paris Cité

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk.

Domaines: Médecine humaine et pathologie

Paul Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, et al.. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376 (16), pp.1527 - 1539. ⟨10.1056/NEJMoa1701488⟩. ⟨hal-01896435⟩